United Therapeutics Corporation (UTHR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 234.47 |
| Open | 233.61 |
| Bid | 236.63 x 100 |
| Ask | 237.20 x 100 |
| Day's Range | 233.61 - 241.00 |
| 52 Week Range | 204.44 - 261.54 |
| Volume | |
| Avg. Volume | 465,895 |
| Market Cap | 11.153B |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | 11.96 |
| EPS (TTM) | 19.81 |
| Earnings Date | May 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 292.25 |
ZacksWill United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ZacksUnited Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireUnited Therapeutics Announces World’s First Successful Xenothymokidney Transplant
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 24, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced, into a living person on April 12, 2024. This transplant represents several historic firsts for transplantation:
© 2024 Yahoo. All rights reserved.